We are no longer recruiting for the following clinical trials which are active now:

Eisai BAN2401-G000-301: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease. Mild Cognitive Impairment MCI to Mild Alzheimer’s Disease.

= Trial is Active No Longer Accepting New Subjects